CR20190273A - Anticuerpos y polipéptidos dirigidos contra cd127 - Google Patents
Anticuerpos y polipéptidos dirigidos contra cd127Info
- Publication number
- CR20190273A CR20190273A CR20190273A CR20190273A CR20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- directed against
- therapeutic
- applications
- polypeptides directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se encuentra el campo de los anticuerpos útiles en aplicaciones terapéuticas y de diagnóstico con diana en CD127, la cadena alfa del receptor de IL7, y provee en particular, anticuerpos monoclonales humanizados contra CD127, particularmente CD127 humano, sus usos terapéuticos y aplicaciones de tipo diagnóstico.The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306655 | 2016-12-09 | ||
| PCT/EP2017/081911 WO2018104483A1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190273A true CR20190273A (es) | 2019-10-17 |
Family
ID=57796143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190273A CR20190273A (es) | 2016-12-09 | 2017-12-07 | Anticuerpos y polipéptidos dirigidos contra cd127 |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US11098128B2 (es) |
| EP (1) | EP3551664B1 (es) |
| JP (1) | JP6986559B2 (es) |
| KR (1) | KR102306366B1 (es) |
| CN (1) | CN110392695B (es) |
| AR (1) | AR110326A1 (es) |
| AU (1) | AU2017373819B2 (es) |
| CA (1) | CA3042582C (es) |
| CL (1) | CL2019001530A1 (es) |
| CO (1) | CO2019005909A2 (es) |
| CR (1) | CR20190273A (es) |
| CY (1) | CY1124153T1 (es) |
| DK (1) | DK3551664T3 (es) |
| EA (1) | EA201991005A1 (es) |
| ES (1) | ES2867900T3 (es) |
| HR (1) | HRP20210697T1 (es) |
| HU (1) | HUE054206T2 (es) |
| IL (1) | IL266837B (es) |
| LT (1) | LT3551664T (es) |
| MA (1) | MA49727B1 (es) |
| MD (1) | MD3551664T2 (es) |
| MX (1) | MX2019006577A (es) |
| MY (1) | MY190770A (es) |
| NZ (1) | NZ753213A (es) |
| PE (1) | PE20191152A1 (es) |
| PH (1) | PH12019501285B1 (es) |
| PL (1) | PL3551664T3 (es) |
| PT (1) | PT3551664T (es) |
| PY (1) | PY1794093A (es) |
| RS (1) | RS61808B1 (es) |
| RU (1) | RU2769352C2 (es) |
| SA (1) | SA519401906B1 (es) |
| SI (1) | SI3551664T1 (es) |
| SM (1) | SMT202100267T1 (es) |
| TW (1) | TWI777996B (es) |
| UA (1) | UA126386C2 (es) |
| UY (1) | UY37511A (es) |
| WO (1) | WO2018104483A1 (es) |
| ZA (1) | ZA201902743B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016239949A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Peptide construct having a protease-cleavable linker |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| EP3405491A1 (en) | 2016-01-21 | 2018-11-28 | VHsquared Limited | Polypeptides |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| EP3635410A4 (en) | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| CN118894938A (zh) | 2019-01-22 | 2024-11-05 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| CA3144566A1 (en) | 2019-06-21 | 2020-12-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| JP7692844B2 (ja) * | 2019-06-21 | 2025-06-16 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| US12570736B2 (en) | 2019-06-21 | 2026-03-10 | Sorriso Pharmaceuticals, Inc. | Compositions |
| MX2022005411A (es) | 2019-11-05 | 2022-08-10 | Medikine Inc | COMPUESTOS DE UNIÓN A IL-2RßYC. |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| US11746139B2 (en) * | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| JP2025518164A (ja) | 2022-05-30 | 2025-06-12 | オセ イムノセラピューティクス | Ｉｌ７ｒモジュレーター活性のバイオマーカー |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| JP2026526546A (ja) * | 2023-07-31 | 2026-08-07 | キュー３２・バイオ・インコーポレーテッド | アトピー性皮膚炎の治療 |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| WO2026022216A1 (en) | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026062296A1 (en) | 2024-09-23 | 2026-03-26 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r |
| WO2026132078A1 (en) | 2024-12-17 | 2026-06-25 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of patients suffering from an inflammatory bowel disease and at high risk of relapse |
| WO2026159138A1 (en) * | 2025-01-21 | 2026-07-30 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and tl1a or tnfrsf25 |
| WO2026159136A1 (en) * | 2025-01-21 | 2026-07-30 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and tnf-alpha |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| CA2787070A1 (en) * | 2010-01-28 | 2011-08-04 | Ian Kirby | Cd127 binding proteins |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 PH PH1/2019/501285A patent/PH12019501285B1/en unknown
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/en not_active Ceased
- 2017-12-07 UY UY0001037511A patent/UY37511A/es active IP Right Grant
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/en active Active
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 CA CA3042582A patent/CA3042582C/en active Active
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active Active
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 SM SM20210267T patent/SMT202100267T1/it unknown
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-11 PY PY201701794093A patent/PY1794093A/es unknown
-
2019
- 2019-05-02 ZA ZA2019/02743A patent/ZA201902743B/en unknown
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
-
2021
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
-
2024
- 2024-03-09 US US18/600,697 patent/US20240352135A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019005909A2 (es) | Anticuerpos y polipéptidos dirigidos contra cd127 | |
| CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| MX2018005613A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
| MX384364B (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| MX2023005881A (es) | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. | |
| MX382129B (es) | Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso. | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| PE20170441A1 (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
| CL2016002247A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| SV2016005352A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| CL2022001138A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| CO2022002808A2 (es) | Proteínas de fusión nkg2d y sus usos | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
| IT201700115761A1 (it) | Bioreattore per la ricellularizzazione e la stimolazione meccanica del diaframma | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. | |
| AR119973A1 (es) | Composiciones y métodos de anticuerpos anti-cd39 | |
| AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение | |
| EA201892257A1 (ru) | Анти-cd3 антитела и способы применения |